These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 9515577)

  • 41. High-dose 5-Fluorouracil with uridine-diphosphoglucose rescue increases thymidylate synthase inhibition but not 5-Fluorouracil incorporation into RNA in murine tumors.
    Codacci-Pisanelli G; Van der Wilt CL; Smid K; Noordhuis P; Voorn D; Pinedo HM; Peters GJ
    Oncology; 2002; 62(4):363-70. PubMed ID: 12138245
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preclinical and clinical trials of topoisomerase inhibitors.
    Saijo N
    Ann N Y Acad Sci; 2000; 922():92-9. PubMed ID: 11193928
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CPT-11 (irinotecan) in the treatment of colorectal cancer.
    Armand JP; Ducreux M; Mahjoubi M; Abigerges D; Bugat R; Chabot G; Herait P; de Forni M; Rougier P
    Eur J Cancer; 1995; 31A(7-8):1283-7. PubMed ID: 7577037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions.
    Haaz MC; Rivory L; Riché C; Vernillet L; Robert J
    Cancer Res; 1998 Feb; 58(3):468-72. PubMed ID: 9458091
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance.
    Kanzawa F; Sugimoto Y; Minato K; Kasahara K; Bungo M; Nakagawa K; Fujiwara Y; Liu LF; Saijo N
    Cancer Res; 1990 Sep; 50(18):5919-24. PubMed ID: 2168285
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
    Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The interaction of buthionine sulphoximide (BSO) and the topoisomerase I inhibitor CPT-11.
    Sawyer TE; Bonner JA
    Br J Cancer Suppl; 1996 Jul; 27():S109-13. PubMed ID: 8763860
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Promising new agents in oncologic treatment.
    Mani S; Ratain MJ
    Curr Opin Oncol; 1996 Nov; 8(6):525-34. PubMed ID: 8971473
    [TBL] [Abstract][Full Text] [Related]  

  • 49. S-phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells.
    O'Connor PM; Nieves-Neira W; Kerrigan D; Bertrand R; Goldman J; Kohn KW; Pommier Y
    Cancer Commun; 1991 Aug; 3(8):233-40. PubMed ID: 1653585
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibitory effects of asiatic acid and CPT-11 on growth of HT-29 cells.
    Bunpo P; Kataoka K; Arimochi H; Nakayama H; Kuwahara T; Vinitketkumnuen U; Ohnishi Y
    J Med Invest; 2005 Feb; 52(1-2):65-73. PubMed ID: 15751275
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.
    McDonald AC; Brown R
    Br J Cancer; 1998 Sep; 78(6):745-51. PubMed ID: 9743293
    [TBL] [Abstract][Full Text] [Related]  

  • 52. O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives.
    Okamoto R; Takano H; Okamura T; Park JS; Tanimoto K; Sekikawa T; Yamamoto W; Sparreboom A; Verweij J; Nishiyama M
    Jpn J Cancer Res; 2002 Jan; 93(1):93-102. PubMed ID: 11802813
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
    Goldwasser F; Bae I; Fornace AJ; Pommier Y
    Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
    Van Cutsem E; Blijham GH
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):13-20. PubMed ID: 10213010
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of SN-38 (an active metabolite of CPT-11) on responses of human and rodent cells to irradiation.
    Sasai K; Guo GZ; Shibuya K; Oya N; Shibata T; Nagata Y; Hiraoka M
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):785-8. PubMed ID: 9845096
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line.
    Arnould S; Guichard S; Hennebelle I; Cassar G; Bugat R; Canal P
    Biochem Pharmacol; 2002 Oct; 64(8):1215-26. PubMed ID: 12234602
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma.
    Gennatas C; Papaxoinis G; Michalaki V; Mouratidou D; Andreadis C; Tsavaris N; Pafiti A
    J Chemother; 2006 Oct; 18(5):538-44. PubMed ID: 17127232
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines.
    van der Wilt CL; Kuiper CM; Peters GJ
    Oncol Res; 1999; 11(8):383-91. PubMed ID: 10803742
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma.
    Yano H; Kayukawa S; Iida S; Nakagawa C; Oguri T; Sanda T; Ding J; Mori F; Ito A; Ri M; Inagaki A; Kusumoto S; Ishida T; Komatsu H; Inagaki H; Suzuki A; Ueda R
    Cancer Sci; 2008 Nov; 99(11):2309-14. PubMed ID: 18771527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.